MedTrace Logo

PET CT With HX4 in Cervix Cancer

NCT02233387 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-03-08

No results posted yet for this study

Summary

The aim of this study is:

1. to determine if tumor hypoxia can be accurately visualised with \[18F\]HX4 PET imaging in cervix cancer,
2. to correlate the \[18F\]HX4 PET images with blood and tissue markers,
3. to investigate the quality and optimal timing of \[18F\]HX4 PET images,
4. to compare \[18F\]HX4 PET uptake with \[18F\]FDG PET uptake before and after treatment and
5. analyze correlation with responses

Conditions

  • Cervix Cancer

Interventions

OTHER

injection with [18F] HX4 and PET imaging

A standard clinical \[18F\]FDG PET-CT will be performed for the radiotherapy planning. After a minimum time interval of 24 hours, baseline \[18F\]HX4 PET scans will be performed: Based on the phase I trial1 444 MBq (12 mCi) \[18F\]HX4 is administrated via a bolus IV injection. The first image acquisition is started together with the administration of \[18F\]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i

Sponsors & Collaborators

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Philippe Lambin, prof MD PhD · Maastro Clinic, The Netherlands

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02233387 on ClinicalTrials.gov